Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Multicenter phase II study with MKC-1 begins
February 27th, 2006
EntreMed, Inc., (ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that it has initiated phase II studies with MKC-1. The single-arm, open-label study will be conducted at approximately 15 centers in the United States. Patients with advanced or metastatic breast cancer who have failed conventional therapies are expected to be enrolled. MKC-1 is an orally active, small-molecule cell cycle inhibitor with a unique mechanism of action. Specifically, MKC-1 arrests cellular mitosis by inhibiting an intracellular target important in cellular trafficking that has been shown to be involved in...
Source: Pharma Business Week (2006-02-27)
|
